Aguiar, Patrícia Melo 
; Lima, T M; Storpirtis, Silvia
Source: Journal of Clinical Pharmacy and Therapeutics. Unidade: FCF
Subjects: MIELOMA MÚLTIPLO, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
AGUIAR, Patrícia Melo e LIMA, T M e STORPIRTIS, Silvia. Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality?. Journal of Clinical Pharmacy and Therapeutics, v. 41, n. 2, p. 189-197, 2016Tradução . . Disponível em: https://doi.org/10.1111/jcpt.12384. Acesso em: 06 out. 2024.APA
Aguiar, P. M., Lima, T. M., & Storpirtis, S. (2016). Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality? Journal of Clinical Pharmacy and Therapeutics, 41( 2), 189-197. doi:10.1111/jcpt.12384NLM
Aguiar PM, Lima TM, Storpirtis S. Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality? [Internet]. Journal of Clinical Pharmacy and Therapeutics. 2016 ; 41( 2): 189-197.[citado 2024 out. 06 ] Available from: https://doi.org/10.1111/jcpt.12384Vancouver
Aguiar PM, Lima TM, Storpirtis S. Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality? [Internet]. Journal of Clinical Pharmacy and Therapeutics. 2016 ; 41( 2): 189-197.[citado 2024 out. 06 ] Available from: https://doi.org/10.1111/jcpt.12384
